BRPI1011031B8 - pharmaceutically acceptable liquid composition and kit - Google Patents

pharmaceutically acceptable liquid composition and kit

Info

Publication number
BRPI1011031B8
BRPI1011031B8 BRPI1011031A BRPI1011031A BRPI1011031B8 BR PI1011031 B8 BRPI1011031 B8 BR PI1011031B8 BR PI1011031 A BRPI1011031 A BR PI1011031A BR PI1011031 A BRPI1011031 A BR PI1011031A BR PI1011031 B8 BRPI1011031 B8 BR PI1011031B8
Authority
BR
Brazil
Prior art keywords
kit
pharmaceutically acceptable
acceptable liquid
levodopa
disease
Prior art date
Application number
BRPI1011031A
Other languages
Portuguese (pt)
Inventor
Nemas Mara
Yacoby-Zeevi Oron
Original Assignee
Neuroderm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42320738&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1011031(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuroderm Ltd filed Critical Neuroderm Ltd
Publication of BRPI1011031A2 publication Critical patent/BRPI1011031A2/en
Publication of BRPI1011031B1 publication Critical patent/BRPI1011031B1/en
Publication of BRPI1011031B8 publication Critical patent/BRPI1011031B8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/10—Hydrazines
    • C07C243/12—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms
    • C07C243/16—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C243/18—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

sal de arginina de um agente ativo, composição líquida ou em gel farmaceuticamente aceitável, kit, método para tratamento de uma desordem neurológica e método para tratar ou amenizar a doença de parkinson em um paciente que necessite deste. divulgados neste documento estão sais de arginina de carbidopa e levodopa e composições que incluem, por exemplo, sal de arginina de carbidopa adequado para administração continua para o tratamento de doenças neurológicas ou motoras ou doenças como a sindrome das pernas inquietas, doença de parkinson, parkinsonismo secundário, psp, msa, als, síndrome shy-drager e condições resultantes e lesão cerebral, incluindo monóxido de carbono ou intoxicação por manganês, juntamente com as administração de levodopa.arginine salt of an active agent, pharmaceutically acceptable liquid or gel composition, kit, method for treating a neurological disorder, and method for treating or alleviating Parkinson's disease in a patient in need thereof. Disclosed herein are arginine salts of carbidopa and levodopa and compositions including, for example, arginine salt of carbidopa suitable for continuous administration for the treatment of neurological or motor diseases or diseases such as restless legs syndrome, parkinson's disease, parkinsonism minor, psp, msa, als, shy-drager syndrome and resulting conditions and brain damage, including carbon monoxide or manganese poisoning, along with levodopa administrations.

BRPI1011031A 2009-05-19 2010-05-17 pharmaceutically acceptable liquid composition and kit BRPI1011031B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17951109P 2009-05-19 2009-05-19
US61/179,511 2009-05-19
PCT/IL2010/000400 WO2010134074A1 (en) 2009-05-19 2010-05-17 Compositions for continuous administration of dopa decarboxylase inhibitors

Publications (3)

Publication Number Publication Date
BRPI1011031A2 BRPI1011031A2 (en) 2016-08-16
BRPI1011031B1 BRPI1011031B1 (en) 2020-06-23
BRPI1011031B8 true BRPI1011031B8 (en) 2021-05-25

Family

ID=42320738

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1011031A BRPI1011031B8 (en) 2009-05-19 2010-05-17 pharmaceutically acceptable liquid composition and kit

Country Status (26)

Country Link
US (9) US8193243B2 (en)
EP (3) EP2432454B1 (en)
JP (3) JP5643297B2 (en)
KR (2) KR101709904B1 (en)
CN (2) CN102438587B (en)
AR (3) AR078413A1 (en)
AU (1) AU2010250766B2 (en)
BR (1) BRPI1011031B8 (en)
CA (1) CA2761624C (en)
CL (1) CL2011002895A1 (en)
CY (1) CY1119495T1 (en)
DK (2) DK3192500T3 (en)
ES (2) ES2840748T3 (en)
HR (2) HRP20170805T1 (en)
HU (2) HUE033388T2 (en)
IL (1) IL216383A (en)
LT (1) LT2432454T (en)
MX (2) MX364974B (en)
NZ (1) NZ596963A (en)
PL (2) PL3192500T3 (en)
PT (2) PT3192500T (en)
RU (3) RU2559083C9 (en)
SG (3) SG10201505101VA (en)
SI (1) SI2432454T1 (en)
WO (1) WO2010134074A1 (en)
ZA (1) ZA201109037B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN192600B (en) * 1996-10-18 2004-05-08 Hoechst Celanese Corp
CN102438587B (en) 2009-05-19 2015-08-19 神经层有限公司 For the compositions of dopa decarboxylase inhibitor continuous administration
AU2011330757B2 (en) * 2010-11-15 2016-05-26 Neuroderm Ltd Continuous administration of L-dopa, dopa decarboxylase inhibitors, catechol-O-methyl transferase inhibitors and compositions for same
NZ703341A (en) 2012-06-05 2016-11-25 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
ITBO20120368A1 (en) 2012-07-06 2014-01-07 Alfa Wassermann Spa COMPOSITIONS INCLUDING RIFAXIMINA AND AMINO ACIDS, RIFAXIMINE CRYSTALS DERIVING FROM SUCH COMPOSITIONS AND THEIR USE.
CN103845318A (en) * 2012-12-07 2014-06-11 天津市汉康医药生物技术有限公司 Entacapone dispersible tablet
RU2677278C2 (en) * 2013-03-13 2019-01-16 Неуродерм Лтд Method for treatment of parkinson's disease
CA2929410C (en) * 2013-11-05 2021-11-09 Synagile Corporation Devices and methods for continuous drug delivery via the mouth
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
DK3116475T3 (en) 2014-03-13 2020-12-07 Neuroderm Ltd DOPA-DECARBOXYLASE INHIBITOR COMPOSITIONS
WO2016036308A1 (en) 2014-09-04 2016-03-10 Lobsor Pharmaceuticals Aktiebolag Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof
EP3209302B1 (en) 2014-10-21 2019-04-24 AbbVie Inc. Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
MA41377A (en) 2015-01-20 2017-11-28 Abbvie Inc LEVODOPA AND CARBIDONA INTESTINAL GEL AND PROCEDURES FOR USE
KR20180004756A (en) 2015-05-06 2018-01-12 신애질 코포레이션 Pharmaceutical suspensions containing drug particles, devices for administration thereof, and methods of use thereof
WO2017039525A1 (en) 2015-09-04 2017-03-09 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
JP2018535230A (en) 2015-11-24 2018-11-29 ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ Pharmaceutical composition comprising levodopaamide and use thereof
WO2017177262A1 (en) * 2016-04-11 2017-10-19 University Of Canberra Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
US10064834B2 (en) 2016-05-09 2018-09-04 Texas Tech University System Carbidopa for the treatment of cancer
JP7134228B2 (en) * 2017-06-05 2022-09-09 ディズリン ファーマシューティカルズ アーベー levodopa infusion
US20230123806A1 (en) * 2017-07-07 2023-04-20 Neuroderm, Ltd. Device for subcutaneous delivery of fluid medicament
WO2019191353A1 (en) * 2018-03-29 2019-10-03 Riverside Pharmaceuticals Corporation Levodopa fractionated dose composition and use
WO2020252257A1 (en) * 2019-06-12 2020-12-17 President And Fellows Of Harvard College Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
KR20240131429A (en) * 2022-01-03 2024-08-30 뉴로덤 엘티디 Methods and compositions for treating Parkinson's disease

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3769424A (en) * 1970-10-01 1973-10-30 Merck & Co Inc Composition and method of treating dopamine deficiency in brain tissue
AU6889274A (en) * 1973-05-17 1975-11-20 Astra Laekemedel Ab Treatment of neurological disorders
US3936495A (en) 1973-11-27 1976-02-03 Merck & Co., Inc. Purification process
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4241082A (en) 1977-09-02 1980-12-23 Sankyo Company Limited Agents for promoting reproductive ability of domestic animals
JPS5450700A (en) 1977-09-28 1979-04-20 Sankyo Co Glazing agent of animal leather
JPS6021570B2 (en) * 1978-07-04 1985-05-28 三共株式会社 Method for manufacturing high concentration preparations of DOPAs
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4642316A (en) 1985-05-20 1987-02-10 Warner-Lambert Company Parenteral phenytoin preparations
ATE76747T1 (en) 1986-06-10 1992-06-15 Chiesi Farma Spa PHARMACEUTICAL COMPOSITIONS CONTAINING LEVODOPA METHYL ESTER, THEIR PREPARATION AND THERAPEUTIC USES.
US4684666A (en) 1986-08-19 1987-08-04 Haas Pharmaceuticals, Inc. Stabilized liquid analgesic compositions
US4963568A (en) 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
WO1992007561A1 (en) 1990-10-30 1992-05-14 Ss Pharmaceutical Co., Ltd. Antiphlogistic and analgesic gel preparation
US5877176A (en) 1991-12-26 1999-03-02 Cornell Research Foundation, Inc. Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis
CA2143070C (en) * 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
GB9523833D0 (en) 1995-11-22 1996-01-24 Boots Co Plc Medical treatment
US5861423A (en) 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US6245917B1 (en) 1998-03-20 2001-06-12 Warner-Lambert Company Crystalline sodium phenytoin monohydrate
US7201923B1 (en) 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
IL139298A0 (en) 1998-05-15 2001-11-25 Warner Lambert Co Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
US6274168B1 (en) 1999-02-23 2001-08-14 Mylan Pharmaceuticals Inc. Phenytoin sodium pharmaceutical compositions
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
AU3490300A (en) 1999-03-12 2000-10-04 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
FI109453B (en) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Pharmaceutical composition
US7479498B2 (en) 1999-08-23 2009-01-20 Phoenix Biosciences, Inc. Treatments for viral infections
US6348965B1 (en) 1999-09-24 2002-02-19 Henry Palladino Solid state fluorescence and absorption spectroscopy
SE0001151D0 (en) 2000-03-31 2000-03-31 Amarin Dev Ab Method of producing a controlled-release composition
US20020028799A1 (en) 2000-07-06 2002-03-07 Naylor Alasdair Mark Treatment of male sexual dysfunction
GB0017387D0 (en) 2000-07-14 2000-08-30 Pfizer Ltd Novel enzyme
US20020099013A1 (en) 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
US20030119714A1 (en) 2000-12-15 2003-06-26 Naylor Alasdair Mark Treatment of male sexual dysfunction
EP1450901A4 (en) 2001-12-10 2005-05-25 Bristol Myers Squibb Co (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase
AU2003214551A1 (en) 2002-04-11 2003-10-20 Ranbaxy Laboratories Limited Controlled release pharmaceutical compositions of carbidopa and levodopa
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
EP1551829B1 (en) 2002-10-10 2010-04-07 Morphochem Aktiengesellschaft Für Kombinatorische Chemie Novel compounds with antibacterial activity
KR101137785B1 (en) 2003-07-18 2012-04-25 백스터 인터내셔널 인코포레이티드 Methods for Fabrication, Uses and Compositions of Small Spherical Particles Prepared by Controlled Phase Separation
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US8173840B2 (en) 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
ATE495739T1 (en) * 2003-08-29 2011-02-15 Transform Pharmaceuticals Inc PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING LEVODOPA AND CARBIDOPA
US20050053669A1 (en) 2003-09-05 2005-03-10 Boehringer Ingelheim International Gmbh Administration form for the oral application of poorly soluble acidic and amphorteric drugs
EP1680083A1 (en) * 2003-10-31 2006-07-19 ALZA Corporation Compositions and dosage forms for ehnanced absorption of iron
CN1901880A (en) * 2003-10-31 2007-01-24 阿尔扎公司 Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin
WO2005099678A1 (en) 2004-04-06 2005-10-27 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
SE0401842D0 (en) 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
ES2572811T3 (en) 2004-09-09 2016-06-02 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing them and methods for obtaining them, and uses thereof
US20060241183A1 (en) 2004-09-28 2006-10-26 Farouk Karoum Compositions and methods of using D-DOPA to treat Parkinson's disease
WO2006043532A1 (en) * 2004-10-19 2006-04-27 Ono Pharmaceutical Co., Ltd. Therapeutic agent for parkinson's disease
DE102006021872B4 (en) 2006-05-11 2008-04-17 Sanofi-Aventis 4,5-Diphenyl-pyrimidinyl-oxy or -mercapto substituted carboxylic acids, process for their preparation and their use as medicaments
RU2484815C2 (en) 2006-05-31 2013-06-20 Зольвай Фармасьютиклз Гмбх Continuous 24-hour introduction of levodopa/carbidopa into intestine
US8058243B2 (en) 2006-10-13 2011-11-15 Hsc Research And Development Limited Partnership Method for treating a brain cancer with ifenprodil
EP2144663A4 (en) * 2007-04-06 2011-06-22 Transform Pharmaceuticals Inc Systems and methods for delivering a fluid drug
CN101669925B (en) 2008-09-10 2011-08-10 天津药物研究院 Dry powder inhalation, preparation method and application thereof
CN102438587B (en) 2009-05-19 2015-08-19 神经层有限公司 For the compositions of dopa decarboxylase inhibitor continuous administration
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
CN101987081B (en) 2010-07-16 2012-08-08 钟术光 Controlled release preparation
KR101187064B1 (en) 2010-07-18 2012-09-28 주식회사 바이오폴리메드 Cationic lipid, method for manufacturing the same and delivery system comprising the same
US10150792B2 (en) 2010-11-08 2018-12-11 Synthonics, Inc. Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients
PT2640370T (en) 2010-11-15 2018-06-15 Neuroderm Ltd Compositions for transdermal delivery of active agents
AU2011330757B2 (en) 2010-11-15 2016-05-26 Neuroderm Ltd Continuous administration of L-dopa, dopa decarboxylase inhibitors, catechol-O-methyl transferase inhibitors and compositions for same
EP2648716A4 (en) 2010-12-10 2015-05-20 Synagile Corp Subcutaneously infusible levodopa prodrug compositions and methods of infusion
US20130116215A1 (en) 2011-10-28 2013-05-09 Mireia Coma Combination therapies for treating neurological disorders
RU2677278C2 (en) 2013-03-13 2019-01-16 Неуродерм Лтд Method for treatment of parkinson's disease
DK3116475T3 (en) 2014-03-13 2020-12-07 Neuroderm Ltd DOPA-DECARBOXYLASE INHIBITOR COMPOSITIONS

Also Published As

Publication number Publication date
KR101641401B1 (en) 2016-07-20
US9993451B2 (en) 2018-06-12
WO2010134074A1 (en) 2010-11-25
BRPI1011031A2 (en) 2016-08-16
CA2761624A1 (en) 2010-11-25
MX364974B (en) 2019-05-16
US20230321019A1 (en) 2023-10-12
NZ596963A (en) 2014-01-31
RU2559083C9 (en) 2016-01-20
SG10201709016RA (en) 2017-11-29
AR117412A2 (en) 2021-08-04
EP2432454A1 (en) 2012-03-28
US20190125708A1 (en) 2019-05-02
US20210077442A1 (en) 2021-03-18
ES2627655T3 (en) 2017-07-31
SG176159A1 (en) 2011-12-29
RU2011149976A (en) 2013-06-27
ES2840748T3 (en) 2021-07-07
AR117502A2 (en) 2021-08-11
PL3192500T3 (en) 2021-04-06
RU2015115064A (en) 2015-11-20
JP6157678B2 (en) 2017-07-05
CA2761624C (en) 2016-10-18
AU2010250766A1 (en) 2012-01-12
JP5643297B2 (en) 2014-12-17
KR20160091424A (en) 2016-08-02
EP3777839A1 (en) 2021-02-17
HRP20170805T1 (en) 2017-08-25
RU2559083C2 (en) 2015-08-10
HUE033388T2 (en) 2017-12-28
RU2019101159A (en) 2020-07-16
US9040590B2 (en) 2015-05-26
ZA201109037B (en) 2013-02-27
JP2016121199A (en) 2016-07-07
US20140249231A1 (en) 2014-09-04
HRP20202038T1 (en) 2021-03-05
IL216383A (en) 2016-02-29
CN102438587A (en) 2012-05-02
SG10201505101VA (en) 2015-07-30
DK2432454T3 (en) 2017-06-19
US9101663B2 (en) 2015-08-11
AU2010250766B2 (en) 2015-04-09
MX2011012315A (en) 2011-12-16
AR078413A1 (en) 2011-11-09
US20160151317A1 (en) 2016-06-02
EP3192500A1 (en) 2017-07-19
CN104546700A (en) 2015-04-29
US20140249230A1 (en) 2014-09-04
EP3192500B1 (en) 2020-12-02
CL2011002895A1 (en) 2012-10-12
RU2678839C2 (en) 2019-02-04
US20100298429A1 (en) 2010-11-25
CN102438587B (en) 2015-08-19
US20110269833A1 (en) 2011-11-03
LT2432454T (en) 2017-07-10
KR101709904B1 (en) 2017-02-23
JP2012527447A (en) 2012-11-08
PT2432454T (en) 2017-06-12
US8193243B2 (en) 2012-06-05
EP2432454B1 (en) 2017-03-01
BRPI1011031B1 (en) 2020-06-23
PT3192500T (en) 2021-01-05
CN104546700B (en) 2017-06-06
IL216383A0 (en) 2012-01-31
PL2432454T3 (en) 2017-10-31
US7863336B2 (en) 2011-01-04
HUE052685T2 (en) 2021-05-28
SI2432454T1 (en) 2017-09-29
US20100298428A1 (en) 2010-11-25
KR20120027371A (en) 2012-03-21
US9040589B2 (en) 2015-05-26
JP5921002B2 (en) 2016-05-24
JP2015017144A (en) 2015-01-29
DK3192500T3 (en) 2020-12-21
CY1119495T1 (en) 2018-03-07

Similar Documents

Publication Publication Date Title
BRPI1011031B8 (en) pharmaceutically acceptable liquid composition and kit
BR112015027282A8 (en) liquid formulation and kit comprising fenfluramine, and uses thereof in the treatment of dravet syndrome
EP3818991A3 (en) Compositions and methods for treating diseases
MX2013007189A (en) Methods and compositions suitable for managing blood glucose in animals.
BR112013026032A2 (en) nutritional compositions including branched chain fatty acids for wound healing
CY1116344T1 (en) CELLS FROM THE Umbilical Cord Web for Neuropathic Pain and Spasticity Therapy
WO2013169864A3 (en) TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
EA201391154A2 (en) METHODS AND COMPOSITIONS FOR ADISCING TO ADIPOCYTES IN MAMMALS
FR2969495B1 (en) EXTRACT OF MACA-RICH AERIAL PARTS OF POLYPHENOLS AND COMPOSITION COMPRISING THE SAME
BR112015015108A2 (en) catheter with markings for easy alignment
CY1115725T1 (en) UNIONS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF BETA-AMYLOIDIC DISEASES AND CONCLUSIONS
BR112013005673A2 (en) use of lysosomal acid lipase for treatment of lysosomal acid lipase deficiency in patients
BR112013020586A2 (en) USE OF UMBILICAL CORD TISSUE DERIVED CELLS
BR112014003071A2 (en) treatment of peripheral vascular disease using umbilical cord tissue derived cells
BR112014001170A2 (en) catheter, especially a permanent catheter, for treating functional problems and / or bladder and / or prostate disease
BR112015019802A2 (en) nitrite pharmaceutical formulations and uses thereof
AU2018253538A1 (en) Levodopa formulations for rapid relief of parkinson&#39;s disease
CO6592030A2 (en) Use of ventricular dilation rate in the treatment of Alzheimer&#39;s disease with intravenous immunoglobulin
IN2014CN03333A (en)
MX2017009325A (en) Levodopa and carbidopa intestinal gel and methods of use.
BR112013025197A2 (en) methods for treating alzheimer&#39;s disease and for evaluating the effectiveness of therapy to treat alzheimer&#39;s disease
CR20110687A (en) PROCEDURES FOR USE OF CORTICOTROPINE RELEASE FACTOR FOR CANCER TREATMENT
MX2022014577A (en) Levodopa and carbidopa intestinal gel and methods of use.
UA112981C2 (en) OPTION OF HUMAN GDNF
BRPI1009892A2 (en) ex vivo method for assessing the efficacy of a treatment in a patient, and kit for testing whether a patient is therapeutically responding to a treatment method comprising administering an immunogenic composition

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DA PRIORIDADE US 61/179,511 DE 19/05/2009 , CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O, ITEM 28 DO ATO NORMATIVO 128/97 E NO ART. 29 DA RESOLUCAO INPI-PR 77/2013. ESTA PERDA SE DEU PELO FATO DE O DEPOSITANTE CONSTANTE DA PETICAO DE REQUERIMENTO DE ENTRADA NA FASE NACIONAL SER DISTINTO DAQUELE QUE DEPOSITOU O PEDIDO ANTERIOR CUJA PRIORIDADE E REIVINDICADA E APRESENTOU COPIA DO CORRESPONDENTE DOCUMENTO DE CESSAO EM 28/02/202012, CONTUDO O PRAZO PARA A APRESENTACAO DA CESSAO DO DIREITO DE PRIORIDADE EXPIRAVA EM 18/01/2012 (60 DIAS APOS A ENTRADA DA FASE NACIONAL DO BRASIL), CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 6O

B12F Other appeals [chapter 12.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/06/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/05/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF